Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
Rhea-AI Summary
Teva (NYSE: TEVA) announced a shared commitment with the Trump Administration to pursue an agreement aimed at lowering costs of select medicines for U.S. Medicaid patients and strengthening supply chain security. The parties are in active discussions, with terms to remain confidential until any final deal is reached.
If completed, the GENEROUS framework would align U.S. Medicaid pricing for certain Teva medicines with leading developed markets, include a prospective Most-Favored-Nation commitment for applicable future innovative launches, and provide a dedicated reserve of selected active pharmaceutical ingredients and continued U.S. manufacturing investment.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 19 | FDA priority review | Positive | +2.5% | FDA accepted ecopipam’s NDA and granted Priority Review for pediatric Tourette syndrome. |
| Aug 11 | Credit rating upgrade | Positive | +0.9% | Moody’s upgraded Teva to investment grade, citing growth execution and debt reduction. |
| Jul 29 | UZEDY sales update | Positive | +9.6% | Record UZEDY sales led Teva to raise its 2026 product revenue outlook. |
| Jul 29 | UZEDY sales update | Positive | +9.6% | UZEDY achieved record quarterly sales and Teva raised its 2026 revenue outlook. |
| Jul 29 | Quarterly earnings report | Positive | +9.6% | Teva reported strong innovative-brand growth and raised outlooks for three key brands. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
All five selected historical events produced positive 24-hour reactions, including a 9.6% move after UZEDY-related news.
Key Terms
most-favored-nation regulatory
active pharmaceutical ingredients technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreement will support continued investment in scientific innovation and pharmaceutical manufacturing capabilities.
“Teva appreciates the opportunity to work with President Trump and his Administration to expand access and affordability for patients today while enabling continued investment in medicines patients need tomorrow,” said Chris Fox, President, Teva USA. “Teva built its business around delivering affordable medicines to Americans, and we share the Administration’s commitment to improve access to more affordable medicines while investing in scientific innovation and domestic manufacturing capabilities in the U.S.”
Teva remains in active discussions with the Trump Administration to strike a deal anchored in all four of the President’s drug pricing priorities. If an agreement is reached, Teva would align U.S. Medicaid pricing for select medicines with pricing in leading developed markets through the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) framework. The agreement also would include a prospective Most-Favored-Nation (MFN) commitment for applicable future innovative product launches. Additionally, Teva has offered a dedicated reserve of certain active pharmaceutical ingredients (API) in support of public health needs and continued investment into U.S. pharmaceutical manufacturing capabilities. Conditions of the negotiation to reach a final agreement remain confidential.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause Teva’s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “developing,” “target,” “may,” “expand,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: the effects of reforms in healthcare regulation and related reductions in pharmaceutical pricing, reimbursement and coverage; U.S. Executive Orders issued in April and May 2025 intended to reduce the prices paid for prescription medicines, including most-favored-nation pricing and related regulatory efforts; our ability to execute the agreement with the U.S. administration to lower the cost of select medicines for patients in the U.S. covered by Medicaid while supporting continued investment in scientific innovation and healthcare system resilience; changes in U.S. administration; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
tevacommunicationsnorthamerica@tevapharm.com
Teva Investor Relations Inquiries
TevaIR@tevapharm.com
